antithyroid drug-induced agranulocytosis
Conditions
Interventions
Antithyroid drug-related agranulocytosis group:None
Antithyroid drug-related granulocytopenia group:None
Antithyroid drug torelance group:None
Normal control group:None
Sponsors
Fujian Medical University Union Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 70 Years
Inclusion criteria
Inclusion criteria: Eligible participants were aged 18 years or older and were able to provide informed consent. Subjects were diagnosed with GD based on clinical and biochemical hyperthyroidism, along with the presence of either thyroid exophthalmos or diffuse goiter and a significant titer of autoantibodies. ATDs, including MMI or PTU, were administered to all patients. Patients were diagnosed with ATD-induced agranulocytosis based on the criteria listed below. First, patients were confirmed to have a granulocyte count greater than or equal to 1.5x10^9/L before they were administered ATDs. Second, the granulocyte count fell below 0.5x10^9/L after ATD administration, and the patients recovered from agranulocytosis after the cessation of ATD treatment. Because 80% of cases of ATD-induced agranulocytosis occur in the first 3 months, the GD control group was composed of subjects with GD who had been treated with ATDs for at least 3 months and had not developed agranulocytosis upon entering the study. All control patients with GD were confirmed to have a normal granulocyte count during the subsequent treatment.
Exclusion criteria
Exclusion criteria: Anticancer chemotherapy within 1 month of onset of agranulocytosis; radiation therapy within the previous month; bone marrow transplantation at any time; ongoing infection with Epstein-Barr virus, hepatitis A virus, HIV, cytomegalovirus, or parvovirus B19; ongoing sepsis; ongoing miliary tuberculosis; current presence of chronic neutropenia (congenital cyclic or idiopathic); ongoing immunosuppressive therapy with cytotoxic drugs; current presence of malignant infi ltration of bone marrow; haematological diseases (eg, myelodysplasia, aplastic anaemia, pancytopenia, and other blood dyscrasias, such as haemoglobin <=100 g/L or platelets <=100x10^9/L); and current presence of systemic lupus erythematosus.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HLA-B;HLA-DRB;SNP; | — |
Countries
China
Contacts
Public ContactYao Chen
Fujian Medical University Union Hospital
Outcome results
None listed